Tags : Self-Administered

GSK’s Nucala (mepolizumab) Receives FDA’s Approval for its Two New

Shots: The approval is based on P-IIIa studies (NCT03099096 & NCT03021304) assessing Nucala in-clinic and at home for patients with severe eosinophilic asthma (SEA). Additionally, a study (NCT03014674) evaluated Nucala’s PK and PD via auto-injector & pre-filled syringe was comparable with approved lyophilised formulation The study resulted in 89-95% and 100% successful self-administered treatment with […]Read More